SAB BIOTHERAPEUTICS, INC. Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
SAB BIOTHERAPEUTICS, INC. (SABS) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of $897.60 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2022-05-12
- SAB BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2022-03-31 was $897.60K, a 157.11% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for the quarter ending 2021-03-31 was $349.12K.
- SAB BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2021 was $2.31M, a 78.68% increase from fiscal 2020.
- SAB BIOTHERAPEUTICS, INC. adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2020 was $1.30M.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 3 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month |
|---|---|---|
| 2022-03-31 | $897.60K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $2.31M 10-K · filed 2022-03-29 | |
| 2021-03-31 | $349.12K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $1.30M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |